Porphyria Targeting Therapies Market

Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

  • Lowest Price Guaranteed From USD 5,899

  • Companies Covered
    0

  • Pages
    124

  • View Count
    11753

Porphyria Targeting Therapies Market Overview

The “Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Porphyria.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Porphyria, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2030.

The context of porphyria targeting therapies market report, published by Roots Analysis List of drug candidates from the research report of Roots Analysis This image highlights the pipeline review of porphyria targeting therapies, prepared by Roots Analysis

Scope of the Report

The “Porphyria Targeting Therapies Market by Type of Drug Class (Biologics and Small Molecules), Type of Porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Erythropoietic Protoporphyria, Hereditary Porphyria, Porphyria Cutanea Tarda, Variegate Porphyria and X-Linked Protoporphyria), Route of Administration (Oral, Intravenous and Subcutaneous) and Key Geographical Regions (US, Canada, UK, France, Germany, Italy, Spain, Netherlands, Australia and Japan): Industry Trends and Global Forecasts: Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future opportunity for the players engaged in developing porphyria targeting therapies. The study presents an in-depth analysis, highlighting the capabilities of various developers engaged in this domain.

This image provides information about completed, ongoing and planned clinical studies of porphyria targeting therapies This image regional mapping of key opinion leaders engaged in porphyria targeting therapies market Competitive analysis of porphyria targeting therapies developers, from Roots Analysis report

Amongst other elements, the report features:

  • A detailed review of the current market landscape of porphyria targeting therapies providing information on phase of development, drug class (biologic, small molecule), route of administration (oral, intravenous, subcutaneous), mechanism of action, type of porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Congenital Erythropoietic Porphyria, Erythropoietic Protoporphyria, Hereditary Coproporphyria, Porphyria Cutanea Tarda, Variegate Porphyria, X-Linked Protoporphyria), drug designations (breakthrough therapy designation, fast track, orphan drug designation)
  • A detailed review of the current market landscape of porphyria targeting therapies developers providing information on year of establishment, headquarters, company size (in terms of employee count), type of player (industry, non-industry) and ownership (public, private, non-profit)
  • An insightful case study on terminated and dormant programs highlighting the terminated and dormant clinical studies in this domain.
  • An in-depth clinical trial analysis providing information on trial status, trial registration year, trial phase, number of patients enrolled, geographical distribution, type of treatment, type of sponsors, active players, study design, type of allocation, type of intervention and type of porphyria.
  • An insightful key opinion leader analysis highlighting the key principal investigators, appointed to lead clinical investigations and examine therapies targeting porphyria using our proprietary scoring based on parameters such as number of publication, number of citations, number of clinical trials, work experience, number of affiliated companies, number of LinkedIn connections and number of affiliated organizations.
  • An insightful competitiveness analysis of the players engaged in the development of therapies targeting porphyria, taking into consideration their portfolio strength (in terms number of drugs in pipeline, phase of development and drug class), number of partnerships, patent portfolio, google hits, year of establishment and size of the company.
  • An analysis of publications that have been published related to this domain based on key parameters such as year of publication, top authors, top journal and emerging focus area.
  • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2010 and 2020, covering product development and commercialization agreement, clinical trial agreement, product development agreement, product licensing agreement and other relevant types of deals. 
  • Elaborate profiles of key players developing porphyria targeting therapies. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team, financial / funding information and product portfolio), recent developments and an informed future outlook.

One of the key objectives of this report was to estimate the existing market size and to estimate the opportunity associated with the porphyria market We have developed informed estimates on the financial evolution of the market, over the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] drug class (biologics and small molecules), [B] route of administration (oral, intravenous and subcutaneous), [C]  type of porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Erythropoietic Porphyria, Hereditary Porphyria, Porphyria Cutanea Tarda, Variegate Porphyria And X-Linked Porphyria) , [D] regional distribution  (US, Canada, UK, Germany, France, Italy, Spain, Netherlands, Australia and Japan),. In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

This image presents review of scientific articles related to porphyria targeting therapies Porphyria Targeting Therapies Market Partnerships and Collaborations The current and future market trends of porphyria targeting therapies market according to Roots Analysis

Key Questions Answered

  • What are the prevalent R&D trends related to Porphyria?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the principal therapies developed by the companies in this domain?
  • Who are the leading industry and non-industry players in this market?
  • What are the key geographies where research on Porphyria is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts in this field?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com